Status:
NOT_YET_RECRUITING
MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies
Lead Sponsor:
University Hospital, Angers
Collaborating Sponsors:
University Hospital, Brest
Institut Paoli-Calmettes
Conditions:
Myeloproliferative Neoplasm
Secondary Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Myeloproliferative neoplasms (MPN) are chronic myeloid malignancies characterized by a risk of evolution to acute myeloid leukemia (AML). This unpredictable complication is associated with a grim outc...
Detailed Description
Patients samples and clinical data: The investigator will study samples from 120 patients with a post-MPN acute myeloid leukemia. These samples and the corresponding clinical data are available throu...
Eligibility Criteria
Inclusion
- Patients with a prior diagnosis of MPN: polycythemia vera, essential thrombocythemia or primary myelofibrosis according to the WHO criteria
- Acute myeloid leukemia evolution defined by ≥ 20% of blasts cells
- Available material from bone marrow sampling at the time of leukemic transformation (i.e. ≥ 20% of blasts cells): DNA (1µg), RNA (500ng) +/- frozen mononuclear cells in DMSO for a subset of 60 patients (2 vials of at least 8 millions cells).
- Informed consent (or requalification procedure)
Exclusion
- \- Patient not affiliated to the French health insurance
Key Trial Info
Start Date :
October 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06022341
Start Date
October 15 2023
End Date
December 31 2028
Last Update
September 1 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.